首页> 外文期刊>American Journal of Physiology >Leukocyte-type 12-lipoxygenase-deficient mice show impaired ischemic preconditioning-induced cardioprotection.
【24h】

Leukocyte-type 12-lipoxygenase-deficient mice show impaired ischemic preconditioning-induced cardioprotection.

机译:白细胞型12脂氧合酶缺陷型小鼠显示缺血预处理引起的心脏保护功能受损。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To investigate the role of 12-lipoxygenase in preconditioning, we examined whether hearts lacking the "leukocyte-type" 12-lipoxygenase (12-LOKO) would be protected by preconditioning. In hearts from wild-type (WT) and 12-LOKO mice, left ventricular developed pressure (LVDP) and (31)P NMR were monitored during treatment (+/-preconditioning) and during global ischemia and reperfusion. Postischemic function (rate-pressure product, percentage of initial value) measured after 20 min of ischemia and 40 min of reperfusion was significantly improved by preconditioning in WT hearts (78 +/- 12% in preconditioned vs. 44 +/- 7% in nonpreconditioned hearts) but not in 12-LOKO hearts (47 +/- 7% in preconditioned vs. 33 +/- 10% in nonpreconditioned hearts). Postischemic recovery of phosphocreatine was significantly better in WT preconditioned hearts than in 12-LOKO preconditioned hearts. Preconditioning significantly reduced the fall in intracellular pH during sustained ischemia in both WT and 12-LOKO hearts, suggesting that attenuation of the fall in pH during ischemia can be dissociated from preconditioning-induced protection. Necrosis was assessed after 25 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride. In WT hearts, preconditioning significantly reduced the area of necrosis (26 +/- 4%) compared with nonpreconditioned hearts (62 +/- 10%) but not in 12-LOKO hearts (85 +/- 3% in preconditioned vs. 63 +/- 11% in nonpreconditioned hearts). Preconditioning resulted in a significant increase in 12(S)-hydroxyeicosatetraenoic acid in WT but not in 12-LOKO hearts. These data demonstrate that 12-lipoxygenase is important in preconditioning.
机译:为了研究12-脂氧合酶在预处理中的作用,我们检查了缺乏“白细胞型” 12-脂氧合酶(12-LOKO)的心脏是否会受到预处理的保护。在野生型(WT)和12-LOKO小鼠的心脏中,在治疗(+/-预处理)以及整体缺血和再灌注过程中监测左心室发育压力(LVDP)和(31)P NMR。缺血20分钟和再灌注40分钟后测得的缺血后功能(比率压力乘积,初始值的百分比)在WT心脏中通过预适应得到了显着改善(预适应为78 +/- 12%,而预适应为44 +/- 7%)。非预处理心脏),但在12-LOKO心脏中则不是(预处理心脏为47 +/- 7%,非预处理心脏为33 +/- 10%)。在WT预处理的心脏中,磷酸肌酸的缺血后恢复明显好于12-LOKO预处理的心脏。预处理显着降低了WT和12-LOKO心脏持续缺血过程中细胞内pH的下降,这表明缺血期间pH下降的减弱可以与预处理诱导的保护分离。使用2,3,5-三苯基四唑鎓氯化物在缺血25分钟和再灌注2小时后评估坏死。在WT心脏中,与未预处理的心脏(62 +/- 10%)相比,预处理显着减少了坏死面积(26 +/- 4%),但在12-LOKO心脏中却没有(在预处理的心脏中为85 +/- 3%vs. 63)在未预处理的心脏中为+/- 11%)。预处理导致WT中的12(S)-羟基二十碳四烯酸显着增加,但在12-LOKO心脏中却没有。这些数据表明12-脂氧合酶在预处理中很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号